linjc16/ctgov huggingface dataset:
Sinonasal Gas Exchange Dynamics

Study Overview
=================
Brief Summary
-----------------
Sinonasal gas exchange is facilitated by the unique anatomy and topography of the sinonasal interface that represents a collection of airfoils creating an aerodynamic structure. The airflow during respiration generates positive and negative pressures that power the gas exchange between the sinuses and the nose. Major surgical alteration of the interface reduces the rate and velocity of the exchange. Minimally invasive procedures aimed at preserving the natural anatomy, topography and aerodynamic configuration of the interface will have negligible effects on sinonasal gas exchange.

Official Title
-----------------
Sinonasal Gas Exchange Dynamics The Aerodynamic Theory of the Sinonasal Interface

Conditions
-----------------
Sinusitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Control: normal healthy adult volunteers ages 18-65, without allergies by history and allergy test, non-smoker, not using steroids. Study group 1: adult subjects who had maxillary sinus balloon sinuplasty (with intact uncinate and ethmoid complex) Study group 2: adult subjects who had endoscopic maxillary antrostomy and uncinectomy. Exclusion criteria: active acute or chronic infection, nasal polyps, severe nasal or septal deformity, cystic fibrosis, systemic illness (diabetes, hypertension etc.), vulnerable population (children, pregnant women, institutionalized individuals etc.) severe nasal and/or septal deviation, hypersensitivity or intolerance to study medications (topical and local anesthetics) any turbinate surgery.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control<br>Healthy adults | |
| Balloon Sinuplasty<br>Patients who had balloon sinuplasty | |
| FESS-Uncinectomy<br>Patients who had FESS-Uncinectomy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sinonasal gas exchange rate | ANALYZE AND DEFINE GAS EXCHANGE PATTERNS IN THE MAXILLARY SINUS DURING NASAL RESPIRATION IN NORMAL SINUSES AND COMPARE WITH SURGICALLY MODIFIED SUBJECTS THAT WILL INCLUDE MAXILLARY SINUSES AFTER ENDOSCOPIC SINUS SURGERY AND BALLOON SINUPLASTY. | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NO production rate | ANALYZE AND DEFINE NITRIC OXIDE PRODUCTION RATE AND VARIABLES IN NORMAL AND SURGICALLY ALTERED MAXILLARY SINUSES | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
nitric oxide, sinuplasty
Formulating Expert Consensus Guidelines in Cancer Care Using the Delphi Method

Study Overview
=================
Brief Summary
-----------------
This study formulates consensus agreement on clinical key elements related to prostate cancer care that are critical for standardization and global reported using a robust Delphi technique, completely remote and electronic. The goal of this survey study is to have a panel of specialty-specific experts create a consensus agreement on a minimum set of key data elements for use in standardized reports. These recommendations would be used to develop standardized methods to report key data in electronic health records to better manage cancer patients at time of diagnosis, treatment, follow up, and into survivorship.

Detailed Description
-----------------
PRIMARY OBJECTIVE: I. To formulate consensus agreement on a minimum set of clinical key elements that should be included in standardized reports in electronic health records when managing patients with prostate cancer. OUTLINE: Participants complete 3-4 rounds of questionnaires over 20-30 minutes each over 2 weeks.

Official Title
-----------------
Key Elements for Standardized Reporting in Prostate Cancer Management: An Expert Delphi Consensus Study

Conditions
-----------------
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm

Intervention / Treatment
-----------------
* Other: Questionnaire Administration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 21 and above Board certification in Radiation Oncology, Radiation Physics, Urology, and/or Medical Oncology Maintenance of an active practice that includes prostate cancer patients English speaking Exclusion Criteria: Medical providers that are not board certified in the professions and/or those who do not treat prostate cancer Prisoners, children, and adults unable to consent to participation will also be excluded No exclusions were made based on sex, age, racial/ethnic background, or pregnancy status

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Observational (questionnaire)<br>Participants complete 3-4 rounds of questionnaires over 20-30 minutes each over 2 weeks. | Other: Questionnaire Administration<br>* Complete questionnaires<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To establish a standardized methods to report key data in electronic health records to better manage cancer patients at time of diagnosis, treatment, follow up, and into survivor-ship. |  | through study completion, an average of a year. |
Scalar Localization Cochlear Electrode Array Using 64 Slice CT

Study Overview
=================
Brief Summary
-----------------
Insertion of electrode array in scala vestibuli, rather than the preferred location within scala tympani, leads to loss of native hearing in those patients with isolated high-frequency hearing loss undergoing cochlear implantation.

Detailed Description
-----------------
We aim to determine the surgical placement in patients with high frequency who had long electrode array insertions because they did not meet audiometric criteria for short array devices. From this basis we will be able to determine if suboptimal insertion (e.g., in the scala vestibuli) leads to loss of low-frequency hearing in these patients. We also will look at the possibilities of using this data in predicting outcomes, modifying implant design, and perfecting surgical technique.

Official Title
-----------------
Scalar Localization of Cochlear Implant Electrode Array in Hearing Preservation Patients Using 64 Slice CT

Conditions
-----------------
Hearing Loss

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Registered in the Cochlear Implant Database. Patient has short or long electrode cochlear implant for high frequency hearing loss. Exclusion Criteria: Inability to provide consent. Patients with underlying otospongiosis, extensive labyrinthitis ossificans or cochlear dysplasia. (These patients would have been identified with pre-operative imaging prior to cochlear implantation).

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Two pediatric participants with high frequency hearing loss post cochlear implant with either long or short electrode array. | |
| 2<br>Eight participants with high frequency hearing loss post cochlear implant with either short or long electrode array. | |
| 3<br>Fifteen participants from the existing Cochlear Implant data base. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The aim of our study is to determine surgical placement of the short electrode of cochlear implants in patients with high frequency loss. |  | Two years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine the surgical placement in patients with high frequency who had long electrode array insertions because they did not meet audiometric criteria for short array devices. |  | Two Years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cochlear, Hearing, High frequency hearing loss
Effect of Cognitive Behavioral Therapy in OCD Highlighted by Neuropsychological Tests and MRI: Pathophysiology and Treatment Outcome Predictors

Study Overview
=================
Brief Summary
-----------------
OCD patients are assessed before and after treatment using diagnostic tools, rating scales neuropsychological assessment and functional and structural MR-scans.

Official Title
-----------------
Effect of Cognitive Behavioral Therapy in OCD Highlighted by Neuropsychological Tests and MRI: Pathophysiology and Treatment Outcome Predictors

Conditions
-----------------
Obsessive-Compulsive Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Steady state medication 3 months prior to the study Exclusion Criteria: History of head trauma or other organic brain disease Pregnancy. Pacemaker or other ferromagnetic materials in the body. Comorbid psychiatric illnesses assessed using SCAN- interview (30) other than moderate depression (Ham-D<17) or anxiety disorders. Antipsychotics

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>OCD patients | |
| 2<br>Normal Controls | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Y-Bocs |  | Before and after treatment approx 20 weeks apart | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Psychological tests, Magnetic Resonance Imaging, Cognitive therapy
Evaluating System Accuracy of Blood Glucose Monitoring Systems for Self-testing in Managing Diabetes Mellitus

Study Overview
=================
Brief Summary
-----------------
In this clinical trial an evaluation of a blood glucose monitoring system (BGStar) and several POCT (point-of-care testing) devices against two laboratory methods will be performed. This evaluation will be performed according to ISO (International Organization for Standardization) 15197 System Accuracy.

Official Title
-----------------
Evaluating System Accuracy of Blood Glucose Monitoring Systems for Self-testing in Managing Diabetes Mellitus [Following EN ISO 15197:2003 - 7.3 System Accuracy Evaluation] Part 40 of Study IDT-2010

Conditions
-----------------
Diabetes

Intervention / Treatment
-----------------
* Device: 7 Blood glucose monitoring systems


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older People with diabetes Typ 1 or Typ 2 and people without diabetes for BG adjustment people with diabetes Typ 1 or Typ 2 informed consent Exclusion Criteria: pregnancy or lactation period severe acute diseases severe chronic diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: 7 Blood glucose monitoring systems|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of System Accuracy according to ISO 15197 |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
POCT, SMBG (self-monitoring of blood glucose), System Accuracy
Pharmacokinetic and Pharmacodynamic Interaction Study of Digoxin and Hawthorn

Study Overview
=================
Brief Summary
-----------------
Hawthorn (Crataegus oxyacantha) is a natural product that is popular in European and American herbal medicine practice. Some of its cardiac uses include the treatment of high and low blood pressure, rapid heart beat, chest pain, and blocked arteries. In many cases, it is used as an adjuvant agent with other cardiac drugs such as digoxin, amiodarone, and warfarin. To date, little information is known about the effect of hawthorn when taken with other drugs and if toxicities occur when hawthorn is used with other drugs. The purpose of this study is to examine the interaction between digoxin and hawthorn in eight healthy subjects. Subjects will be recruited by advertisement. The design of the study will include a 10-day and a three-week treatment phase of digoxin 0.125 mg - 0.25 mg/day and hawthorn (Crataegus special extract WS1442, Schwabe Co.) 450 mg twice daily or placebo, with a randomized crossover. There will be a three-week washout period in between treatment phases. On day 10 (phase I) and day 21 (phase II), subjects will have 12 blood samples drawn for pharmacokinetic analysis. The plasma samples will be measured for digoxin concentration. Additionally, the subjects will be assessed for any clinical toxicities or adverse events. The significance of this study is to provide the clinician with information regarding the safe use of digoxin in combination with the herbal supplement, hawthorn.

Conditions
-----------------
Heart Diseases

Intervention / Treatment
-----------------
* Drug: Digoxin
* Drug: Hawthorn


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy adult Not regularly taking any prescription or non-prescription medications (including natural products or supplements) and is willing to avoid all medications other than the study drugs during the study period. Willing to avoid drinking any alcohol throughout the study period. Does not currently smoke and is willing to avoid smoking during the study period. Willing to adhere to dietary restrictions as required during the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Digoxin|nan|
|Drug: Hawthorn|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Digoxin, Effect modifiers (Epidemiology), Rosales, Drug Interaction
Effects of a Late Phase Exercise Program Following Total Hip Arthroplasty

Study Overview
=================
Brief Summary
-----------------
A group of orthopedic physiotherapists have developed a late phase program to educate and instruct total hip replacement patients in progressive exercises appropriate for their level of recovery. The components of this program include an educational presentation, individual assessment and exercise prescription. The investigators' intent is to pilot the program using a sample of patients. The objective of this pilot project: To examine the effects of the late phase education session and home-based exercise program in restoring hip muscle strength, gait and function

Official Title
-----------------
Effects of a Late Phase Education and Exercise Program Following Total Hip Arthroplasty: A Pilot Project

Conditions
-----------------
Total Hip Arthroplasty

Intervention / Treatment
-----------------
* Other: home based exercise and education program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: unilateral primary total hip arthroplasty (THA) 8-12 weeks post THA over the age of 18 able to walk 15m without a walking aid able to participate in an exercise program without physical assistance available for follow up as per the study protocol able to read and understand English and follow verbal and visual instructions Exclusion Criteria: medically unstable have central or peripheral nervous system deficits have an underlying terminal disease (cancer) have suspicion of infection following joint replacement

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| THA control<br>those with THA not participating in exercise and education program | |
| THA exercise<br>those with THA and participating in exercise and education program | Other: home based exercise and education program<br>* Individual assessment with physiotherapist with educational information, exercise instruction and prescription provided. Instructed to perform home exercises and walking for 12 weeks. Will be individually tailored to participants, bi-monthly phone calls will be used to monitor and facilitate exercise and walking progression .<br>|
| healthy control<br>Healthy control, people with no lower limb gait abnormalities | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hip muscle strength |  | 8-12 weeks post THA, 6-7 months post THA | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gait |  | 8-12 weeks post THA, 6-7 months post THA | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Unilateral total hip arthroplasty
Comparision of FIBTEM and Blood-loss

Study Overview
=================
Brief Summary
-----------------
Correlation between FIBTEM and intraoperative blood loss

Conditions
-----------------
Sternotomy, Bleeding Test

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: full sternotomy age >18 Inform consent signed Exclusion Criteria: Hypofibrinogen

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| open heart surgery<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bleeding |  | intraoperative | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
5 minute bleeding test, swamb, fibtem, extem
Studying RNA in Samples From Younger Patients With T-Cell Acute Lymphoblastic Leukemia

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer PURPOSE: This laboratory study is looking into RNA in samples from younger patients with T-cell (T) acute lymphoblastic leukemia (ALL).

Detailed Description
-----------------
OBJECTIVES: Characterization of the transcriptomic landscape in diagnosis and relapse of T-cell acute lymphoblastic leukemia (ALL) and the direct comparison with corresponding physiological samples (human thymus). Perform high-throughput transcriptome ribonucleic acid (RNA) sequencing using matched diagnostic T-precursor pediatric ALL samples (peripheral blood or bone marrow). OUTLINE: Archived peripheral blood and bone marrow samples are analyzed for long non-coding RNA (IncRNA) expression and sequencing.

Official Title
-----------------
Molecular Taxonomy in Pediatric Cancer- IncRNA Expression in Primary T-ALL

Conditions
-----------------
Leukemia

Intervention / Treatment
-----------------
* Genetic: RNA analysis
* Genetic: proteomic profiling
* Other: laboratory biomarker analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Peripheral blood and bone marrow samples from pediatric patients with diagnosed and relapsed T-ALL PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: Not specified
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: RNA analysis|nan|
|Genetic: proteomic profiling|nan|
|Other: laboratory biomarker analysis|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification and characterization of IncRNA of pediatric T-cell acute lymphoblastic leukemia |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
T-cell childhood acute lymphoblastic leukemia, recurrent childhood acute lymphoblastic leukemia